Country: Canada
Language: English
Source: Health Canada
CAFFEINE CITRATE
CHIESI FARMACEUTICI S.P.A.
N06BC01
CAFFEINE
20MG
SOLUTION
CAFFEINE CITRATE 20MG
INTRAVENOUS
15G/50G
Prescription Recommended
Respiratory and CNS Stimulants
Active ingredient group (AIG) number: 0162054001; AHFS:
APPROVED
2020-03-04
_Product Monograph- Peyona_ _TM_ _ _ _Page 1 of 25_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr PEYONA TM CAFFEINE CITRATE INJECTION AND CAFFEINE CITRATE ORAL SOLUTION MFR. STD. 20 MG / ML SOLUTION, INTRAVENOUS / ORAL (EACH ML CONTAINS 20 MG CAFFEINE CITRATE, EQUIVALENT TO 10 MG CAFFEINE BASE) PSYCHOANALEPTICS, XANTHINE DERIVATIVES ATC CODE: N06BC01 SPONSOR : Chiesi Farmaceutici SpA Via Palermo 26/A 43122 Parma Italy DATE OF INITIAL CREATION: March 3, 2020 IMPORTED BY: Methapharm Inc 81 Sinclair Boulevard Brantford, ON N3S 7X6 Canada Submission Control No: 225810 _ _ _Product Monograph- Peyona_ _TM_ _ _ _Page 2 of 25 _ TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................4 1 INDICATIONS ..................................................................................................................4 Pediatrics ..............................................................................................................................4 Geriatrics ..............................................................................................................................4 2 CONTRAINDICATIONS .................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................5 4 DOSAGE AND ADMINISTRATION .............................................................................5 Dosing Considerations .........................................................................................................5 Recommended Dose and Dosage Adjustment .....................................................................5 Administration .....................................................................................................................7 5 OVERDOSAGE ........................................... Read the complete document